ReviewFrontiers in cardiovascular medicine2026
Research progress on the mechanism of panax notoginseng saponin in the treatment of atherosclerosis.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing incidence and prevalence of atherosclerosis (AS), it has become a major global public health concern. While interventional surgery and Western medicines are effective in treating AS, their adverse effects are noteworthy. Traditional Chinese medicine offers the advantage of low side effects and significant therapeutic effects, making its active ingredients potential candidates for new medicine development. Panax notoginseng saponin (PNS), a compound derived from the natural drug panax notoginseng, has shown significant efficacy in AS treatment by targeting six main aspects: anti-inflammation, regulation of lipid metabolism, anti-oxidative stress, inhibition of vascular smooth muscle cell proliferation and migration, inhibition of angiogenesis, and regulation of autophagy. This study reviews the pharmacological mechanisms of PNS in AS treatment, as well as its biological properties,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.